2022 / 03

Следующая статья
DOI: 10.24075/medet.2022.053

ОБЗОР

Клинико-экономические и этические аспекты оценки исходов терапии пациентов с множественной миеломой высокого цитогенетического риска

Ю. А. Заболотнева, К. Г. Гуревич
Информация об авторах

Московский государственный медико‑стоматологический университет им. А. И. Евдокимова, Москва, Россия

Для корреспонденции: Юлия Александровна Заболотнева
ул. Делегатская, д. 20/1, г. Москва, 127473, Россия; moc.liamg@liam4891ailu

Информация о статье

Вклад авторов: Ю. А. Заболотнева — сбор, анализ и синтез материала, написание статьи; К. Г. Гуревич — идея статьи, написание.

Статья получена: 19.07.2022 Статья принята к печати: 24.08.2022 Опубликовано online: 29.11.2022
|
  1. Sonneveld P, Avet‑Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high‑risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127: 2955–2962.
  2. Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. 2020 Aug 11; 10 (8): 82. DOI: 10.1038/ s41408–020–00348–5. PMID: 32782240; PMCID: PMC7419564.
  3. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23: 3412–3420.
  4. Palumbo A, Avet‑Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33 (26): 2863–9. DOI: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3. PMID: 26240224; PMCID: PMC4846284.
  5. Mayo Clinic. (2021). Mayo stratification for myeloma and risk‑adapted therapy: relapsed myeloma. Available from mSMART: A clear and simple guide for treating patients with multiple myeloma — Mayo Clinic (Accessed 9 December 2021).
  6. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet‑Loiseau H; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb; 28 (2): 269–77. DOI: 10.1038/ leu.2013.247. Epub 2013 Aug 26. PMID: 23974982.
  7. Caro J., Al Hadidi S, Usmani S, Yee A, Raje N, Davies F. How to Treat High‑Risk Myeloma at Diagnosis and Relapse DOI: 10.1200/ EDBK_320105 American Society of Clinical Oncology Educational Book. May 19, 2021; 41: 291–309.
  8. Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real‑World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. Adv Hematol. 2019 Jan 29; 2019: 4625787. DOI: 10.1155/2019/4625787. PMID: 30838045; PMCID: PMC6374830.
  9. Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib‑Dexamethasone versus Bortezomib‑Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019; 19: 522–530.e1.
  10. Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten‑Kumeli A, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open‑label, phase 3 study. Lancet 2020; 396: 186–197.
  11. Richardson, P.G.; Kumar, S.K.; Masszi, T.; Grzasko, N.; Bahlis, N.J.; Hansson, M.; Pour, L.; Sandhu, I.; Ganly, P.; Baker, B.W.; et al. Final Overall Survival Analysis of the TOURMALINE‑MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. J Clin Oncol Off. J Am Soc Clin Oncol. 2021; 39: 2430–2442.
  12. Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/ refractory multiple myeloma: Extended follow‑up of POLLUX, a randomized, open‑label, phase 3 study. Leukemia 2020; 34: 1875–1884.
  13. Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/ refractory multiple myeloma: Extended 4‑year follow‑up and analysis of relative progression‑free survival from the randomized ELOQUENT‑2 trial. Cancer. 2018; 124: 4032–4043.
  14. Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, Kuriakose ET, Migliaccio‑Walle K. Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework. Am Health Drug Benefits. 2015; 8: 204–215.
  15. International Monetary Fund (IMF). SDRs per Currency Unit for July 2021. Available online: https://www.imf.org/external/np/fin/data/rms_mth.aspx?SelectDate=2021–07–31&reportType=SDRCV (accessed on 13 August 2021).
  16. Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. Eur J Cancer. 2020; 129: 41–49.
  17. World Health Organization. Pricing of Cancer Medicines and Its Impacts; World Health Organization: Geneva, Switzerland, 2018. Available online: https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115‑eng.pdf?sequence=1&isAllowed=y (accessed on 10 April 2020).
  18. Cook R. Economic and clinical impact of multiple myeloma to managed care. J. Manag. Care Plus Spec Pharm. 2008; 14: 19–25.
  19. Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017; 31: 1915–1921.
  20. Nadler E, Eckert B, Neumann P. Do oncologists believe new cancer drugs offer good value? The Oncologist. 2006; 11: 90–5.
  21. Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high‑risk multiple myeloma (SWOG‑1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021; 8: e45‑e54.
  22. Durie BGM, Hoering A, Sexton R, et al. Longer term follow‑up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020; 10: 53.
  23. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem‑cell transplant (SWOG S0777): a randomised, open‑label, phase 3 trial. Lancet. 2017; 389: 519–527.
  24. Mateos M–V, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378: 518–528.
  25. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380: 2104–2115.
  26. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem‑cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open‑label, phase 3 study. Lancet. 2019; 394: 29–38.
  27. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant‑eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136: 936–945.
  28. Hari P, Pasquini MC, Stadtmauer EA, et al. Long‑term follow‑up of BMT CTN 0702 (STAMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020; 38(suppl; abstr 8506).
  29. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019; 37: 589–597.
  30. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem‑cell transplantation versus bortezomib‑melphalanprednisone, with or without bortezomiblenalidomidedexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/ HO95): a multicentre, randomised, open‑label, phase 3 study. Lancet Haematol. 2020; 7: e456– e468.
  31. Sonneveld P, Beksac M, Van Der Holt B, et al. Consolidation treatment with VRD followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant‑eligible patients with multiple myeloma (MM): a randomized phase 3 trial of the European Myeloma Network (EMN02/HO95). Blood. 2020; 136(suppl): 46–48.